VISCHER advises Endosense, a pioneer and leader in force-sensing technology focused on improving the efficacy and safety of catheter ablation for the treatment of cardiac arrhythmias, in an USD 40.3 million/CHF 37.4 million series C financing. Led by new investor NGN Capital, the round draws large participation from all existing investors, including Edmond de Rothschild Investment Partners, NeoMed Management, Gimv, VI Partners, Sectoral Asset Management, Ysios Capital Partners and Initiative Capital Romandie, as well as multiple employees. The VISCHER team includes Matthias Staehelin (Partner) and Laura Rey (Associate).